Lumos today closed $1.31 or almost a $200M Market Cap. Atomo...

Lumos today closed $1.31 or almost a $200M Market Cap. Atomo represents huge value and leverage from this price.

We have several deals across different diseases underpinning our growth. We are selling shovels to the miners.

1. Lumos Diagnostics with FebriDx Viral and Bacterial product with a long term supply agreement
2. Access Bio recent FDA approved Covid 19 Antibody test with substantial demand anticipated over the medium term
3. Viatris (ex Pfizer) HIV Test for the developing world with demand of c.25M Self HIV tests by 2025 globally.
4. NG Biotech Rapid Pregnancy Test and Covid

The below is from the Lumos Prospectus:

In the US, there are an estimated 150m inpatient and outpatient interactions each year for patients with ARI for whom FebriDx® could be used. Assuming reimbursement coverage of approximately US$16 per FebriDx® test (an estimate based on existing reimbursement codes for C-reactive protein (CRP) and infectious disease immunoassays), the total addressable market for bacterial versus viral detection in the United States would be US$2.4 billion per year.

FebriDx is the first and only rapid, all-in-one POC test device which only Atomo can deliver and is a company maker in itself for both companies.